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HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance
between antibodies and with in-situ hybridisation
Aims: Treatment with anti-HER2 therapy could be
beneficial for patients with HER2-positive endometrial
and ovarian clear cell carcinoma (CCC). We studied
HER2 overexpression by immunohistochemistry (IHC)
using three different antibodies, including concor-
dance with amplification by in-situ hybridisation
(ISH).
Methods and results: IHC and ISH were performed on
tissue microarrays of 101 tumours: 58 endometrial
pure CCC, 19 endometrial mixed carcinomas with a
CCC component and 24 ovarian pure CCC. IHC was
performed using SP3, 4B5 and HercepTest antibodies,
and was scored by two independent observers. ISH
was performed using dual-colour silver ISH. Using
IHC, agreement was poor between SP3/4B5 (61.4%),
poor between SP3/HercepTest (68.3%) and reason-
able between 4B5/HercepTest (75.2%). Interobserver
agreement was substantial to almost perfect for all
antibodies (SP3: linear weighted j = 0.89, 4B5:
j = 0.90, HercepTest: j = 0.76). HER2-positivity by
ISH was 17.8% (endometrial pure CCC: 24.1%,
endometrial mixed: 0%, ovarian pure CCC: 16.7%).
IHC/ISH concordance was poor, with a high false-
negative rate of all three IHC antibodies: sensitivity
(38.9–50.0%) and positive predictive value (PPV)
(37.5–58.3%) were poor; specificity (81.9–94.0%)
and negative predictive value (NPV) (87.1–88.3%)
were reasonable. When excluding 2+ cases, sensitiv-
ity declined (26.7–43.8%) but PPV (80.0–87.5%) and
specificity (98.6–98.7%) improved.
Conclusions: In ovarian and endometrial CCC, there
is considerable difference in HER2 overexpression by
different IHC antibodies and marked discordance with
ISH. As such, no single antibody can be considered
conclusive for determining HER2 status in CCC. Based
on these results, the lack of predictive value of differ-
ent HER2 testing methods, as used in other studies,
could be explained.
Keywords: endometrial cancer, human epidermal growth factor 2 (HER2), immunohistochemistry (IHC), in-situ
hybridisation (ISH), ovarian cancer
Introduction
Endometrial and ovarian cancer are common malig-
nancies in women, responsible for 4% (endometrial)
and 5% (ovarian) of cancer-related female deaths.1
Most endometrial and ovarian cancers are epithelial
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tumours, mainly endometrioid and serous carci-
noma.2–4 The third subtype is clear cell carcinoma
(CCC), accounting for up to 2–5% of endometrial and
5–25% of ovarian carcinomas.4–8 CCC is a high-grade
adenocarcinoma, associated with aggressive clinical
behaviour and poor prognosis.8–10 Additionally, a
‘mixed’ endometrial carcinoma subtype exists, con-
taining at least 5% of multiple subtypes.11 In
endometrial mixed carcinoma with a serous compo-
nent, tumour behaviour correlates with the highest
grade (serous) component. A CCC component in
mixed carcinoma might therefore be clinically rele-
vant, but few data are available on these
tumours.11,12 The mixed carcinoma category for
ovarian carcinoma was abandoned in the most recent
World Health Organization (WHO) classification
(2014).11
Treatment options for endometrial and ovarian
CCC are limited. Response to traditional treatment
with surgery, radiotherapy or chemotherapy is poorer
than other high-grade carcinomas.5–7 Molecular
alterations in CCC are being identified, and strategies
with targeted therapies are still in development.9,13
The current concept of precision cancer medicine
strives for a patient tailored approach. Therefore, it is
crucial to define individual tumour characteristics. A
possible target for therapy is the human epidermal
growth factor receptor 2 (HER2/ErbB2), well known
from its clinical significance in HER2-positive breast-
and gastroesophageal cancer.14–22 In endometrial
and ovarian cancer, HER2-positivity varies consider-
ably: 17–80% in endometrial and 8–66% in ovarian
carcinoma.23–25 Specific data on CCC are scarce, with
14–67% HER2-positivity reported in small patient
cohorts (often n < 10).25–37 Results of anti-HER2
therapy in endometrial and ovarian carcinoma to
date are inconsistent.31,36–46 No clinical data of anti-
HER2 therapy in CCC are available. However, the def-
inition of HER2-positivity between studies varies
widely.
HER2 status can be determined by quantifying cell
membrane overexpression with immunohistochem-
istry (IHC) or by assessing gene amplification with in-
situ hybridisation (ISH). ISH is considered the ‘gold
standard’ in breast- and gastroesophageal cancer,
with high predictive value of IHC.22,47 However,
HER2 testing is not standardised in endometrial and
ovarian carcinoma. Additionally, IHC overexpression
by different HER2 antibodies can vary.26,48–50
Although concordance between HER2 antibodies in
breast- and gastroesophageal cancer is high,22,47,51
this has not been established for endometrial and
ovarian cancer. Studies on endometrial and ovarian
CCC to date have applied different criteria, using
either IHC or ISH and often not both.25–37 Studies
with IHC used various HER2 antibodies and none
have compared different antibodies.
The aim of this study was to compare HER2 over-
expression by different IHC antibodies and their con-
cordance with HER2 amplification by ISH in a large
cohort of patients with endometrial and ovarian CCC.
Materials and Methods
P A T I E N T S
Formalin-fixed paraffin-embedded tumour tissue avail-
able for tissue microarray (TMA) was obtained from
curettages, biopsies or resection specimens of patients
with endometrial CCC (pure or mixed with a CCC
component) treated in the University Medical Center
Groningen (UMCG, the Netherlands) in 1984–2016
or in the Isala Hospital Zwolle (the Netherlands) in
2006–2016, and of patients with ovarian CCC trea-
ted in the UMCG in 2000–2012. All cases were
reviewed by two gynaecopathologists to confirm the
diagnosis of pure CCC or mixed carcinoma with a
CCC component (endometrial cases: H.H. and J.B.;
ovarian cases: H.H. and E.D.; only cases with a con-
cordant diagnosis between both pathologists were
included). This yielded 103 patients: 24 ovarian pure
CCC, 60 endometrial pure CCC and 19 endometrial
mixed carcinomas, 18 of which were mixed
endometrioid/CCC [CCC component: mean = 36%
(23.5% standard deviation; range = 5–80%)] and
one mixed serous/CCC (CCC component: 20%). All
ovarian samples contained pure CCC. During the
course of the study two cases were excluded due to
unsuccessful ISH, resulting in a study population of
101 patients (Figure 1, patient characteristics in
Table 1).
Patient material was handled following the ‘Code of
conduct for health research’ of the Dutch Federation
of Biomedical Scientific Societies.52 Data were filed in
a separate anonymous database. Therefore, no addi-
tional permission from our Ethics Committee was
required.
T M A C O N S T R U C T I O N A N D H E R 2 C O N T R O L S
TMAs were constructed using a manual microarrayer
(Beecher Instruments, Silver Spring, MD, USA); two
TMAs with 0.6 mm endometrial tumour cores, one
TMA with 1 mm ovarian tumour cores. Of every
patient, three to six tumour cores were obtained. This
included three selective cores of both components in
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mixed carcinomas. Tissues from various other organs
were included as controls. Standardised HER2 con-
trols were included in all IHC and ISH tests (Breast
Dynamic Range Analyte Control; HistoCyte Laborato-
ries, Newcastle upon Tyne, UK). Uniform staining of
these controls was assured on all slides. 3-lm sec-
tions were cut for IHC and ISH.
I M M U N O H I S T O C H E M I S T R Y
IHC for 4B5 (PATHWAY anti-HER2/neu (4B5) rabbit
monoclonal antibody; Ventana Medical Systems, Ill-
kirch, France) and SP3 (rabbit monoclonal antibody;
NeoMarkers, Fremont, CA, USA) were performed on
the Ventana BenchMark Ultra. 4B5 was prediluted,
SP3 diluted 1:40. Antigen retrieval time was
64 min (95°C, cell conditioning 1, pH 9; Ventana);
incubation time with the primary antibody was
32 min. Visualisation was achieved with the
ultraView diaminobenzidine detection kit (Ventana),
including antigen amplification (Ventana Amplifica-
tion Kit). Counterstaining was performed with
Mayer’s haematoxylin (Klinipath, Breda, the
Netherlands).
IHC for HercepTest (rabbit polyclonal antibody
A0485; Dako, Carpentaria, CA, USA) was performed
in the Autostainer Link 48 (Dako) using the Her-
cepTest Kit SK001 (Dako). This includes antigen
retrieval (40 min, 97°C) in PT Link (Dako), incuba-
tion with the primary antibody (30 min) and incuba-
tion with the visualisation complex (30 min).
Counterstaining was performed with Mayer’s haema-
toxylin (SK308; Dako).
All three antibodies are used in daily clinical prac-
tice on breast- and gastroesophageal cancer, follow-
ing the manufacturer’s protocols with standardised
staining kits (as described above). SP3 and 4B5 are
used in the UMCG; HercepTest is used in the
Ovarian CCC
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Figure 1. Flow-chart of the
study population formation.
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Maasstad Hospital (Rotterdam, the Netherlands). All
antibodies were validated internally, including com-
parison with ISH results. SP3 and HercepTest have
been subjected to external proficiency testing with
NordiQC in 2017, with ‘good’ and ‘optimal’ results.
Additionally, adequate antibody performance during
the study was ensured on the standardised HER2
controls.
I N - S I T U H Y B R I D I S A T I O N
Dual-colour silver ISH was performed with the
INFORM HER2 Dual ISH DNA probe cocktail (Ven-
tana) on the Ventana BenchMark Ultra. Pretreatment
was with cell conditioning 2 (Ventana; 36 min,
86°C, three cycles) and enzyme digestion with ISH
protease 3 (12 min), followed by incubation with
HER2 (dinitrophenol-labelled) and chromosome 17
(CEP17, digoxigenin-labelled) probes for 4 min.
Probes were denatured (20 min, 80°C) and hybri-
dised (6 h, 80°C), followed by appropriate stringency
washes (three times, 8 min, 74°C). The HER2 probe
(black dots) was visualised by incubation with anti-
dinitrophenol antibody (20 min) and horseradish per-
oxidase-conjugated antibody (32 min) followed by sil-
ver reactions (8 min). The CEP17 probe (red dots)
was visualised by incubation with anti-digoxigenin
antibody (20 min) and alkaline phosphatase-conju-
gated antibody (24 min) followed by red ISH Naphtol
reaction (8 min). Slides were counterstained with
Ventana hematoxylin II and bluing reagent. Ade-
quate ISH performance was ensured on the standard-
ised HER2 controls.
I H C A N D I S H E V A L U A T I O N
IHC stains of 4B5, SP3 and HercepTest were scored
independently by an experienced pathologist (B.V.)
and a senior resident (T.K.). HER2 expression was
graded using the standard semi-quantitative scale;53
0: no staining or membrane staining in ≤10% of
tumour cells; 1+: faint/barely perceptible partial
membrane staining in >10%; 2+: weak-to-moderate
complete membrane staining in >10%; and 3+:
strong complete membrane staining in >10%. The
highest IHC score by either observer was used as the
score for the case.
ISH was evaluated according to current breast can-
cer guidelines47 by calculating the HER2/CEP17 ratio
and the average HER2 copy number in 20 tumour
cells: negative: ratio <2.0, copy number <4.0; posi-
tive: ratio ≥2.0 or ratio <2.0, copy number ≥6.0; and
equivocal: ratio <2.0, copy number ≥4.0/<6.0. In
equivocal cases, 20 additional tumour cells were
counted.
For both IHC and ISH, the highest score in one of
the TMA cores was considered representative for the
case (in accordance with the 10% cut-off).47
Heterogeneity was defined as either a different ISH
result, or IHC score difference of >1 point with at
least one antibody by at least one observer.
P 5 3
Additional p53 IHC was performed on all endometrial
carcinomas, using the anti-p53 monoclonal mouse
antibody BP53-11 (Ventana) on the Ventana









Age at diagnosis (years)
Mean
(SD)
66 (12) 70 (10) 63 (16) 59 (9)
Range 39–92 44–89 39–92 45–83
FIGO stage (n, %)
I 44 (44.9) 30 (54.5) 7 (36.8) 7 (29.2)
II 10 (10.2) 5 (9.1) 2 (10.5) 3 (12.5)
III 36 (36.7) 13 (23.6) 9 (47.4) 14 (58.3)
IV 8 (8.2) 7 (12.7) 1 (5.3) 0 (0)
Unknown 3 3 0 0
CCC, Clear cell carcinoma; FIGO, International Federation of Gynaecology and Obstetrics; SD, Standard deviation.
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Benchmark Ultra, following the manufacturer’s proto-
col. p53 staining was differentiated in physiological
wild-type expression and mutational overexpression.
Overexpression was defined as diffuse strong staining
in tumour cell nuclei.
S T A T I S T I C S
For agreement between observers, linear weighted
kappa (j) statistics were performed in R for Windows
version 3.3.2 (R Foundation, Vienna, Austria), using
the ‘irr’ package. j values were interpreted as <0.2,
slight; 0.21–0.40, fair; 0.41–0.60, moderate; 0.61–
0.80, substantial; and 0.81–1.00, almost perfect
agreement.54 For IHC/ISH concordance, IHC results
were compared to ISH as the ‘gold standard’. Sensi-
tivity, specificity, positive predictive value (PPV) and
negative predictive value (NPV), including 95% con-
fidence intervals, were calculated in two analyses. In
the first analysis IHC 2+ cases were considered posi-
tive, because 2+ is commonly considered positive in
literature on HER2 in endometrial and ovarian car-
cinoma. In the second analysis IHC 2+ cases were
excluded, as in breast- and gastroesophageal cancer
2+ is ‘equivocal’ and not predictive of ISH amplifica-
tion.22,47 p53 overexpression rates in HER2-positive
and -negative endometrial carcinomas were com-
pared using Fisher’s exact test (two-sided, P < 0.05
considered significant) in IBM SPSS Statistics for Win-
dows version 23.0.0.3 (SPSS, Inc., Chicago, IL,
USA).
Results
I M M U N O H I S T O C H E M I S T R Y
IHC results for the three different antibodies are dis-
played in Table 2. Agreement between SP3 and 4B5
was 61.4%; between SP3 and HercepTest was 68.3%;
and between 4B5 and HercepTest was 75.2%. Exam-
ples of concordant cases are shown in Figure 2, dis-
cordant cases in Figure 3. The SP3 antibody showed
more staining and resulted in higher scores than 4B5
and HercepTest. 4B5 showed more cases without any
staining (score 0) than SP3 and HercepTest. These
discrepancies occurred in both observers, with high
interobserver agreement: 89.1% (SP3, j = 0.89; ‘al-
most perfect’), 89.0% (4B5, j = 0.90; ‘almost per-
fect’) and 81.2% (HercepTest, j = 0.76: ‘substantial’)
(Table S1). The discordance between antibodies
occurred in both endometrial and ovarian pure CCC,
with both observers (Table S2).
H E R 2 P R E V A L E N C E
HER2-positivity by IHC and ISH is displayed in
Table 3. By ISH, HER2-positivity was 17.8% in the
total study population (n = 101); 24.1% in endome-
trial pure CCC (n = 58), 0% in endometrial mixed
carcinoma with a CCC component (n = 19) and
16.7% in ovarian pure CCC (n = 24). The ISH ampli-
fication ratios of HER2-positive cases are shown in
Table S3. All TMA cores of all components of the
Table 2. Comparison of IHC scores using different HER2
antibodies
4B5
0 1 2 3 Total
SP3 0 44 1 1 0 46
1 22 9 0 0 31
2 1 11 4 0 16
3 0 1 2 5 8
Total 67 22 7 5 101
Agreement: 61.4%
HT
0 1 2 3 Total
SP3 0 40 6 0 0 46
1 12 17 2 0 31
2 1 8 7 0 16
3 0 1 2 5 8
Total 53 32 11 5 101
Agreement: 68.3%
HT
0 1 2 3 Total
4B5 0 51 15 1 0 67
1 2 15 5 0 22
2 0 2 5 0 7
3 0 0 0 5 5
Total 53 32 11 5 101
Agreement: 75.2%
IHC, Immunohistochemistry; HER2, Human epidermal growth fac-
tor 2; SP3, SP3 antibody; 4B5, 4B5 antibody; HT, HercepTest anti-
body.
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 73, 852–863.
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endometrial mixed carcinomas were HER2-negative
by ISH and by IHC (0/1+) with all three antibodies.
I H C / I S H C O N C O R D A N C E
IHC/ISH concordance is shown in Table S4. Sensitiv-
ity, specificity, PPV and NPV of all IHC antibodies
with ISH as a reference are shown in Table 4. Includ-
ing 2+ scores, there was a high false-negative rate of
IHC by all three antibodies, resulting in poor sensitiv-
ity (38.9–50.0%) and PPV (37.5–58.3%) with rea-
sonable specificity (81.9–94.0%) and NPV (87.1–
88.3%). When excluding 2+ scores, many ISH-nega-








Figure 2. Human epidermal growth factor 2 (HER2) immunohistochemistry (IHC) with concordant staining between different antibodies:
SP3 (left row), 4B5 (middle row) and HercepTest (right row) with score 0 (A–C), score 1+ (D–F), score 2+ (G–I) and score 3+ (J–L). Insets:
examples of negative in-situ hybridisation (ISH) (diploid: inset of C) and positive in-situ hybridisation (ISH) (amplified: inset of L).
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 73, 852–863.
HER2 in gynaecological clear cell carcinoma 857
sensitivity declined (26.7–43.8%) but PPV (80.0–
87.5%) and specificity improved (98.6–98.7%), with
identical NPV (87.1–88.3%).
H E T E R O G E N E I T Y
Heterogeneity between TMA cores of the same
tumour occurred in only nine cases (8.9%), either as
a different ISH result (n = 3) or IHC score difference
of >1 point with at least one antibody by at least one
observer (n = 6).
P 5 3
Results of p53 IHC, performed on all endometrial
carcinomas, are displayed in Table 5. In endometrial
mixed carcinomas, p53 staining was identical in
both components of all tumours. Interestingly, p53
overexpression was much more frequent in HER2-
positive endometrial pure CCC than in HER2-nega-
tive endometrial pure CCC (11 of 13 = 84.6% versus
15 of 40 = 37.5%; P = 0.002) and HER2-negative
endometrial mixed carcinoma (11 of 13 = 84.6%




Figure 3. Discordant human epidermal growth factor 2 (HER2) immunohistochemistry (IHC) between different antibodies. Example 1
showed 2+/3+ staining with SP3 (A) but was 1+ with both 4B5 (B) and HercepTest (C). Example 2 was completely negative (score 0) with
SP3 (D) but showed 2+ staining with 4B5 (E) and faint 1+ staining with HercepTest (F). In-situ hybridisation (ISH) was positive in both
cases (amplified: insets of C and F).







Endometrial mixed with a CCC
component (n = 19)
Ovarian pure CCC
(n = 24)
ISH amplified 18 (17.8%) 14 (24.1%) 0 (0%) 4 (16.7%)
IHC 2+/3+, SP3 24 (23.8%) 21 (36.2%) 0 (0%) 3 (12.5%)
IHC 2+/3+, 4B5 12 (11.9%) 9 (15.5%) 0 (0%) 3 (12.5%)
IHC 2+/3+, HT 16 (15.8%) 13 (22.4%) 0 (0%) 3 (12.5%)
HER2, Human epidermal growth factor 2; CCC, Clear cell carcinoma; ISH, in-situ hybridisation; IHC, Immunohistochemistry; SP3, SP3 anti-
body; 4B5, 4B5 antibody; HT, HercepTest antibody.
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 73, 852–863.
858 T Koopman et al.
no significant difference in p53 expression between
HER2-negative endometrial pure CCC and HER2-
negative endometrial mixed carcinoma (15 of
40 = 37.5% versus three of 19 = 15.8%;
P = 0.132).
Discussion
Targeted treatment of the HER2 receptor might be
beneficial for patients with HER2-positive CCC. In a
large cohort of patients with endometrial or ovarian
CCC, we compared HER2 overexpression by IHC
using different antibodies and established their con-
cordance with ISH amplification. To the best of our
knowledge, this is the first study to compare different
HER2 antibodies in these tumours. We found
discordance between three antibodies. For all antibod-
ies the predictive value of HER2 amplification by ISH
was poor.
Data on HER2-positivity in endometrial and ovar-
ian CCC are scarce. Studies on endometrial carcinoma
included few CCC (usually n < 10), among which
HER2-positivity varied between 16 and 67% (IHC
and ISH).25–30,37 In a larger cohort of 58 endometrial
pure CCC cases, we found 24.1% HER2-positivity by
ISH and 15.5–36.2% by IHC (2+/3+), which is in line
with these studies. Larger studies are available for
ovarian CCC (n = 5–92), showing 14–46% HER2-
positivity rates by IHC or ISH.31–36 We found 16.7%
HER2-positivity by ISH and 12.5% by IHC (2+/3+) in
24 ovarian pure CCC cases, which is lower than or
comparable to these studies. To the best of our
knowledge, no studies exist on HER2-positivity in
endometrial mixed carcinoma with a CCC component.
Interestingly, we found that in this subgroup of our
study (n = 19), all tumours were HER2-negative in
all components by both ISH and IHC. The carcino-
genic pathways leading to pure CCC and mixed carci-
noma therefore seem to differ, and it seems unlikely
that patients with endometrial mixed carcinoma with
a CCC component will benefit from anti-HER2
therapy.
The difference of HER2-positivity rates reported in
the literature could be due to different methods and
criteria used to establish HER2 status. ISH amplifica-
tion is considered the ‘gold standard’ in breast- and
gastroesophageal cancer,55–57 with high predictive
value of IHC overexpression57,58 and high
Table 4. Sensitivity, specificity and predictive values (in %) for IHC using different antibodies with ISH as a reference
Sensitivity (95%CI) Specificity (95%CI) PPV (95%CI) NPV (95%CI) Total (n) 2+ (n, %)
Including cases with IHC 2+ score
SP3 50.0 (26.8–73.2) 81.9 (71.6–89.2) 37.5 (19.6–59.2) 88.3 (78.5–94.2) 101 16 (15.8%)
4B5 38.9 (18.3–63.9) 94.0 (85.9–97.8) 58.3 (28.6–83.5) 87.6 (78.6–93.4) 101 7 (6.9%)
HT 38.9 (18.3–63.9) 89.2 (79.9–94.5) 43.8 (20.8–69.4) 87.1 (77.6–93.1) 101 11 (10.9%)
Sensitivity (95%CI) Specificity (95%CI) PPV (95%CI) NPV (95%CI) Total (n)
Excluding cases with IHC 2+ score
SP3 43.8 (20.8–69.4) 98.6 (91.1–99.9) 87.5 (46.7–99.3) 88.3 (78.5–94.2) 85
4B5 26.7 (8.9–55.2) 98.7 (92.2–99.9) 80.0 (29.9–98.9) 87.6 (78.6–93.4) 94
HT 26.7 (8.9–55.2) 98.7 (91.8–99.9) 80.0 (29.9–98.9) 87.1 (77.6–93.1) 90
IHC, immunohistochemistry; ISH, in-situ hybridisation; CI, confidence interval; PPV, positive predictive value; NPV, negative predictive
value; SP3, SP3 antibody; 4B5, 4B5 antibody; HT, HercepTest antibody.











p53 wild-type 2 (15.4%) 25 (62.5%) 16 (84.2%)
p53
overexpressed
11 (84.6%) 15 (37.5%) 3 (15.8%)
Missing 1 4 –
Total 14 44 19
CCC, Clear cell carcinoma; HER2, Human epidermal growth factor 2.
*All endometrial mixed carcinoma cases were HER2 negative.
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concordance between antibodies.22,47,51 IHC score 0/
1+ is considered negative; 2+ equivocal (subsequent
ISH should follow); and 3+ positive. In contrast,
HER2 testing is not standardised in endometrial and
ovarian carcinoma, and concordance between HER2
antibodies has not been established. Most studies,
including endometrial and ovarian CCC, applied IHC
without ISH, often with 2+/3+ scores considered posi-
tive, and none have compared IHC antibodies (most
use HercepTest). Although no data on endometrial
CCC are specifically available, IHC/ISH discordance is
known to occur in endometrial carcinoma in general,
with higher overexpression than amplification
rates.24–26 On ovarian CCC, only one study imple-
mented IHC and ISH on all cases, reporting 14%
HER2-positivity (six of 50 cases) with perfect IHC/ISH
concordance (2+/3+ classified positive with Her-
cepTest).34 In our study, IHC/ISH concordance was
poor in both endometrial and ovarian CCC, even
when we excluded IHC 2+ scores (in which discor-
dance with ISH can be expected due to the equivocal
nature of 2+). Although this occurred with all three
antibodies, there were also considerable differences
between these antibodies. Possible explanations for
different antibody performances are individual anti-
body sensitivity and specificity, but also technical dif-
ferences in staining methods (such as dilution,
epitope retrieval method and incubation times).26,48–
50 Additionally, pre-analytical factors such as tissue
size, fixative type, fixation time and temperature dur-
ing fixation and processing could influence antibody
sensitivity.59 We included samples from only two lab-
oratories, in which tissue processing has been consis-
tent for years. To circumvent technical artefacts, our
study included standardised HER2 controls in which
uniform antibody behaviour was assured.
The inconsistency of IHC and ISH could also
explain the inconsistent results of studies on anti-
HER2 therapy in endometrial and ovarian carcinoma
to date. Anti-HER2 therapy is an established part of
breast- and gastroesophageal cancer treatment.14–22
Trastuzumab was shown to reduce ovarian CCC cell
lines in vitro,36 but no clinical data of anti-HER2
therapy in endometrial or ovarian CCC are available.
In other endometrial carcinoma subtypes, clinical
activity of trastuzumab has been described in several
case reports.38–40 Several Phase II studies on endome-
trial carcinoma37,41 as well as ovarian carcinoma31,42–
46 have shown a poor response to anti-HER2 therapy
with trastuzumab, pertuzumab or lapatinib, but these
studies did not include CCC or did not specify
response per subtype. The reason for these poor
results could be inconsistent HER2 testing among
these studies, which applied enzyme-linked
immunosorbent assay (ELISA),42 reverse transcrip-
tion–polymerase chain reaction (RT–PCR),43 IHC
without ISH31,38,39,41,45 or ISH without IHC.40,42
One study did not establish HER2 status at all.44
Some studies included HER2-negative patients.41,42,45
The only clinical study which included CCCs using
both IHC and ISH based HER2-positivity on IHC (2+/
3+ with HercepTest), while almost half these patients
(15 of 33; 45.5%) lacked ISH amplification.37 This
study included only three endometrial CCCs and did
not specify results within this subgroup. Very
recently, encouraging results with anti-HER2 therapy
were achieved in a Phase II study on endometrial ser-
ous carcinoma, where the addition of trastuzumab to
standard chemotherapy increased progression-free
survival in patients with HER2-positive tumours.60 In
this study, HER2-positivity was defined as an IHC 3+
score, or IHC 2+ with ISH amplification. However,
the IHC antibody was not specified, while the differ-
ences in antibody performance in endometrial CCC,
as shown in our study, might also be a concern in
endometrial serous carcinoma.
In addition to differences in HER2 testing, another
mechanism which may explain poor response to anti-
HER2 therapy is the loss of HER2 expression in
metastases. This was shown in a recent study on
endometrial cancer, which included 790 endometrial
carcinomas, including 30 CCCs.61
Yet another possible explanation of the variable
results of anti-HER2 therapy in endometrial and ovar-
ian carcinoma is the mechanism leading to HER2
amplification. The amplification ratios of HER2-posi-
tive tumours in our study were generally lower than
in breast cancer (25–29% of cases with HER2/CEP17
ratio >5.0, versus >50% in breast cancer). ISH ampli-
fication with relatively low amplification ratios may
reflect aneuploidy or polysomy in carcinomas with
high copy number abnormalities, rather than being
the driver event with HER2 gene amplification seen
in breast- and gastroesophageal cancer.
We found that p53 overexpression is more com-
mon in HER2-positive than in HER2-negative
endometrial carcinomas. p53 mutations are associ-
ated with chromosomal instability, i.e. aneuploidy or
polysomy, and with amplification instability, i.e. gene
amplification.62 Co-existence of p53 and HER2 over-
expression also occurs in breast cancer, in which
HER2 overexpression is related to gene amplifica-
tion.63 In ovarian and endometrial carcinoma, p53
overexpression could be related to HER2 overexpres-
sion due to either aneuploidy or amplification; the
underlying mechanism is unknown.
© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd, Histopathology, 73, 852–863.
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A potential limitation of our study is the use of
TMAs, as TMA cores can miss relevant data and
HER2 staining can be heterogeneous. Heterogeneity
between TMA cores occurred in only nine (8.9%) of
our study cases, but it is unknown whether this rep-
resents whole sections. However, studies have shown
that taking at least three tumour cores, as was per-
formed in our study, results in adequate representa-
tion of the whole section staining pattern and, as
such, largely obviates heterogeneity issues.64,65 More-
over, the use of TMAs was not a limitation with
regard to the comparison of IHC antibodies and IHC/
ISH comparison, as identical cores were compared
directly.
Although ISH is considered the ‘gold standard’ for
HER2 status in breast- and gastroesophageal cancer,
some patients with IHC-positive/ISH-negative tumours
can benefit from anti-HER2 therapy and some patients
with IHC-negative/ISH-positive tumours might not
respond to anti-HER2 therapy.22,47,55–57 Anti-HER2
therapy has been successful in breast cancer patients
with polysomy and normal HER2/CEP17 ratios.66 A
HER2-positive subgroup in patients with endometrial
and ovarian CCC could benefit from anti-HER2 ther-
apy, but it is unknown whether IHC or ISH would be a
better predictor of clinical outcome.
In conclusion, we found considerable differences in
HER2 overexpression by different IHC antibodies, as
well as discordance with HER2 amplification by ISH,
in a large cohort of patients with endometrial and
ovarian CCC. Therefore, no single IHC antibody can
be considered to be conclusive when determining
HER2 status in these tumours. Based on these results
the lack of predictive value of different HER2 testing
methods, as used in other studies, can possibly be
explained. As some patients may benefit from anti-
HER2 therapy, future studies should include HER2
testing with different IHC antibodies as well as ISH,
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